clinical trial approvals
13 evaluated products received clinical trial approvals,
including 8 Category 1 new drugs.
Led by experts with extensive NMPA new drug review experience
Core team members hold advanced degrees with years of biological evaluation expertise
Strict adherence to NMPA's GLP standards
Maintain over 100 animal/cell models and 300+ SOPs
Robust quality management system
Established China's first non-human primate asthma model
Filled a critical gap in domestic research capabilities
Premier capability in antibacterial drug efficacy evaluation
Collaborative access to hejiang Province P2/P3 laboratories
Ensures precise and reliable assessments
| Asthma Models | OVA-induced Asthma Model | Rats、Mice、Guinea pigs |
House Dust Mite-induced Asthma Model | Mice | |
Antigen-induced Asthma Model | Non-human primates | |
COPD Models | Acute Cigarette Smoke-Induced COPD Model | Mice |
Chronic Cigarette Smoke-Induced COPD Mode | Rats | |
Cigarette Smoke + LPS-Induced COPD Mode | Rats | |
Pulmonary Fibrosis Models | Bleomycin-Induced Pulmonary Fibrosis Model | Rats、Mice |
Silica-Induced Pulmonary Fibrosis Model | Rats、Mice | |
Pneumonia Models | LPS-Induced Pneumonia Model | Rats、Mice |
PM2.5-Induced Pneumonia Model | Mice | |
Bacterial Infection-Induced Pneumonia Model | Mice | |
Bronchoconstri-ction/Bronchodi-lation Models | Methacholine (Mch)-Induced Bronchoconstriction Model | Guinea pigs |
Histamine (His)-Induced Bronchoconstriction Model | Guinea pigs | |
Guinea Pig Isolated Tracheal Smooth Muscle Contraction Model | Guinea pigs | |
Pseudomonas aeruginosa Infection-Induced Bronchiectasis Model | Rats、Mice | |
Pulmonary Edema Models | High Altitude Pulmonary Edema Model | Rats |
LPS-Induced Pulmonary Edema Model | Mice | |
Pulmonary Hypertension Models | Monocrotaline-Induced Rat Pulmonary Hypertension Model | Rats |
Hypoxia-Induced Rat Pulmonary Hypertension Model | Rats | |
Cough Models | Ammonia-Induced Mouse Cough Model | Mice |
Citric Acid-Induced Guinea Pig Cough Model | Guinea pigs | |
Rhinitis Models | OVA-Induced Allergic Rhinitis Model | Rats、Guinea pigs |
Antigen-Induced Rhinitis Model | Non-human primates | |
Substance P-Induced Rhinitis Model | Mice | |
Eosinophilic Chronic Rhinosinusitis Model | Mice |
Inflammation & Autoimmune Disease Models | DNCB-induced Atopic Dermatitis Model (Mouse) Antigen-induced Skin Allergy Test Xylene-induced Ear Edema Model (Mouse) Hot Plate Test (Mouse Pain Model) Acetic Acid-induced Writhing Test (Mouse) LPS-induced Fever Model (Rat) Yeast-induced Fever Model (Rabbit) Rat Capillary Expectoration Model Mouse Tracheal Phenol Red Secretion Model Mouse Peritoneal Capillary Permeability Model Collagen-induced Rheumatoid Arthritis Model (Mouse) Adjuvant-induced Rheumatoid Arthritis Model (Rat) Sodium Monoiodoacetate-induced Knee Osteoarthritis Model (Rat/Mouse) OVA-induced Conjunctivitis Model (Rat) Antigen-induced Conjunctivitis/Dermatitis Model (Monkey) IgA-induced Nephrotic Syndrome Model (Rat) |
Organoid Models | Airway Organoids Alveolar Organoids Skin Organoids Airway Remodeling Organoid Model |
Neurological Models | Kainic Acid-induced Epilepsy Model (Rat) Pilocarpine-induced Epilepsy Model (Mouse) Social Defeat Stress Depression Model Chronic Restraint Stress Depression Model Forced Swim Test Sucrose Preference Test Parkinson's Disease Models Alzheimer's Disease Models Tail Suspension Test |
Cell-based Models | Cellular Inflammation Models Cellular Fibrosis Models UV/H₂O₂-induced Fibroblast Models (Cosmetic efficacy evaluation: firming, anti-wrinkle, anti-aging, anti-photoaging) UV/H₂O₂-induced Keratinocyte Models (Cosmetic efficacy evaluation: sunscreen, antioxidant, repair, soothing) HEK293T RAR/RXR Luciferase Reporter Assay (Transcriptional activity detection) TNF-α-induced Cellular Senescence Inflammation Model UV-induced P65 Nuclear Translocation Model Cellular Epilepsy Models Fibroblast Spheroid UVR Photoaging Model |
Drug Name | Registration Category | Approval Date | Indication |
|---|---|---|---|
| CM338 | Therapeutic Biological Products Category 1 | IgA Nephropathy | |
| CM326 | Therapeutic Biological Products Category 1 | Asthma, Chronic Rhinosinusitis with Nasal Polyps, Atopic Dermatitis | |
EB070 Injection | Therapeutic Biological Products Category 1 | 2023.11.09 | Asthma |
| XH-6003 | Chemical Drugs Category 1 | 2021.10.21 | Cerebral Edema |
101BHG-D01 Nasal Spray | Chemical Drugs Category 1 | 2020.12.14 | Post-Cold Rhinitis and Persistent Allergic Rhinitis symptoms: Rhinorrhea, Sneezing |
HRS-9821 Inhalation Suspension | Chemical Drugs Category 1 | 2024.07.11 | Chronic Obstructive Pulmonary Disease (COPD) Maintenance Therapy |
DBM-1152A Inhalation Solution | Chemical Drugs Category 1 | 2023.06.21 | COPD (including chronic bronchitis and emphysema) for acute Bronchospasm Relief，Maintenance Treatment |
| CM512 | Therapeutic Biological Products Category 1 | 2024.11.07 | Moderate-to-Severe Atopic Dermatitis |
Drug Name | Registration Category | Approval Date | Approval Number | Indication |
|---|---|---|---|---|
Dermatophagoides Farinae Drops | Therapeutic Biological Products Category 4 | 2010.07.20 | National Drug Approval S20060012 | Allergic Rhinitis, Asthma |
| Pingchuan Yiqi Keli | Traditional Chinese medicines | 2017.11.21 | National Drug Approval Z20050258 | Facilitating lung function, tonifying Qi, relieving cold-type asthma |
Ambroxol Hydrochloride Solution for Inhalation | Chemical Drugs Category 5.2 | 2019.07.11 | J20190023 | Acute/Chronic Respiratory Diseases with thick Sputum , expectoration Difficulty |
Bencycloquidium Bromide Nasal Spray | Chemical Drugs Category 1 | 2020.03.19 | National Drug Approval H20200003 | Persistent Allergic Rhinitis, Post-Cold Rhinitis symptoms |
Ambroxol Hydrochloride Nebuliser Solution | Chemical Drugs Category 3 | 2020.12.21 | National Drug Approval H20203668 | Acute/Chronic Respiratory Diseases with thick Sputum , expectoration Difficulty |
| CM310 | Therapeutic Biological Products Category 1 | 2022.10.14 | National Drug Approval S20240040 | Atopic Dermatitis |
